1 2 3 4 5

The per-protocol effect of immediate versus deferred antiretroviral therapy initiation

Lodi, Sara; Sharma, Shweta; Lundgren, Jens D.; More

AIDS . 30(17):2659-2663, November 13, 2016.

Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?

Jarrin, Inma; Pantazis, Nikos; Dalmau, Judith; More

AIDS . 29(17):2323-2333, November 2015.

Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM

Phillips, Andrew N.; Cambiano, Valentina; Miners, Alec; More

AIDS . 29(14):1855-1862, September 10, 2015.

  • Open Access Icon

HIV resistance testing and detected drug resistance in Europe

Schultze, Anna; Phillips, Andrew N.; Paredes, Roger; More

AIDS . 29(11):1379-1389, July 17, 2015.

Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease

Borges, Álvaro H.; Weitz, Jeffrey I.; Collins, Gary; More

AIDS . 28(12):1791-1796, July 31, 2014.

Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression

O’Connor, Jemma L.; Smith, Colette J.; Lampe, Fiona C.; More

AIDS . 28(6):919-924, March 27, 2014.

Associations between immune depression and cardiovascular events in HIV infection

Sabin, Caroline A.; Ryom, Lene; De Wit, Stephane; More

AIDS . 27(17):2735-2748, November 13, 2013.

Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies

Kaulich-Bartz, Josee; Dam, Wayne; May, Margaret T.; More

AIDS . 27(10):1641-1655, June 19, 2013.

CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use

Mocroft, Amanda; Phillips, Andrew N.; Gatell, Jose; More

AIDS . 27(6):907-918, March 27, 2013.

Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events

Monforte, Antonella d’Arminio; Reiss, Peter; Ryom, Lene; More

AIDS . 27(3):407-415, January 28, 2013.

The incidence of lymphoma in the UK haemophilia population between 1978 and 1999

Wilde, Jonathan T.; Lee, Christine A.; Darby, Sarah C.; More

AIDS . 16(13):1803-1807, September 6, 2002.

Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?

Moore, Antonia L.; Youle, Mike; Lipman, Marc; More

AIDS . 16(4):615-618, March 8, 2002.

Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals

Phillips, Andrew N.; Miller, Veronica; Sabin, Caroline; More

AIDS . 15(18):2379-2384, December 7, 2001.

Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients

Phillips, Andrew N.; Pradier, Christian; Lazzarin, Adriano; More

AIDS . 15(18):2385-2395, December 7, 2001.

When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study

Lepri, Alessandro Cozzi; Phillips, Andrew N.; d'Arminio Monforte, Antonella; More

AIDS . 15(8):983-990, May 25, 2001.

Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir

Kirk, Ole; Mocroft, Amanda; Pradier, Christian; More

AIDS . 15(8):999-1008, May 25, 2001.

Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre

Mocroft, Amanda; Youle, Michael; Moore, Antonia; More

AIDS . 15(2):185-194, January 26, 2001.

The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study

Mocroft, Amanda; Phillips, Andrew N.; Miller, Veronica; More

AIDS . 15(2):201-209, January 26, 2001.

The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load

Miller, Veronica; Sabin, Caroline A.; Phillips, Andrew N.; More

AIDS . 14(14):2129-2136, September 29, 2000.

Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens

Youle, Mike; Janossy, George; Turnbull, Wayne; More

AIDS . 14(12):1717-1720, August 18, 2000.

Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population

Mocroft, Amanda; Devereux, Helen; Kinloch-de-Loes, Sabine; More

AIDS . 14(11):1545-1552, July 28, 2000.

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients

Monforte, Antonella d'Arminio; Lepri, Alessandro Cozzi; Rezza, Giovanni; More

AIDS . 14(5):499-507, March 31, 2000.

Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials

Phillips, Andrew N.; Grabar, Sophie; Tassie, Jean-Michel; More

AIDS . 13(15):2075-2082, October 22, 1999.

The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997

Mocroft, Amanda; Barry, Simon; Sabin, Caroline A.; More

AIDS . 13(10):1255-1261, July 9, 1999.

Disease progression and survival following specific AIDS‐defining conditions: a retrospective cohort study of 2048 HIV‐infected persons in London

Petruckevitch, Ann; Amo, Julia Del; Phillips, Andrew N.; More

AIDS . 12(9):1007-1013, September 1998.

Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals

Phillips, Andrew N.; Eron, Joseph; Bartlett, John; More

AIDS . 11(2):169-175, February 11, 1997.

1 2 3 4 5